Business Wire

Delticom AG: Biker Summer 2016: Most Bikers Travel Several Thousand Kilometres Every Year

Del

For the fourth time, Moto-tyres.co.uk, the online biker shop from Delticom, Europe’s largest online tyre retailer, asked bike fans from ten European countries about their preferred biking summer. Over 5,000 bike fans from throughout Europe provided details of their biking preferences. This means that more than four times as many riders took part in the survey as last year. Participants were eligible to win prizes worth over 2,000 euros - including high-quality accessories for their next trip, and vouchers for a new set of tyres.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161213005708/en/

Biker Summer 2016: Most bikers travel several thousand kilometres every year (Photo: Business Wire)

Biker Summer 2016: Most bikers travel several thousand kilometres every year (Photo: Business Wire)

The results of the survey paint a picture of the typical European biker. All participants answered three questions which tracked the plans of bike lovers: about their planned tour lengths in kilometres, as well as in numbers of days, and their preferred brand of tyres.

British bikers

Just over a third (34%) of British bikers were planning tours with a total length between 3,000 and 5,500 kilometres. This showed a preference for trips which can be completed over a long weekend: for the majority of respondents (23%), their longest trip would last between two and five days. When it comes to tyre brands, the Brits bet on European products and premium brands: the most popular manufacturers are Michelin, Bridgestone, and Metzeler.

“We are delighted to have convinced so many bikers across Europe to complete our survey. Finding out about their individual preferences was fun and exciting. The results show the extent to which the sport of motorbiking fascinates people - from hobby bikers who prefer short weekend breaks, to real enthusiasts, who will happily be on the road for more than two weeks, and who will cover more than 12,000 kilometres during their trip. This wide variety of driving profiles must, of course, be reflected in the choice of tyres on offer”, says Oliver Pflaum of Moto-tyres.co.uk. “Bikers often know exactly which set-up suits them and their machine. That’s why we offer a comprehensive range.”

With just a few clicks, Moto-tyres.co.uk customers can find the perfect tyres for their motorbike - thanks to the intuitive website, transparent structure, and simple navigation. The Moto-tyres.co.uk range also includes accessories and spare parts for motorbikes, as well as motorbike tyre inner tubes and engine oil.

About Moto-tyres.co.uk

Whether you're looking for chopper, sport-touring or scooter tyres: bikers will find everything their heart desires in this renowned online store's range. Accessories such as bike tubes and motor oil complete Delticom's bike range. The two-wheeler tyre specialist's portfolio includes all established premium bike tyre manufacturers such as Metzeler, Pirelli, Continental, Dunlop, Bridgestone and Michelin, as well as renowned quality brands such as Heidenau, Avon, Maxxis and Mitas.

Online store for end users: www.moto-tyres.co.uk

Further online stores in Europe: www.MotorradreifenDirekt.de (DE), www.MotorradreifenDirekt.at (AT), www.MotorradreifenDirekt.ch (CH), www.pneus-moto.fr (FR), www.motorbandenmarkt.nl (NL), www.moto-pneumatici.it (IT), www.neumaticosdemoto.es (ES) and more.

Online store for dealers: www.yourtyres.co.uk

About the company: www.delti.com

Contact information

insignis Communications Agency GmbH (GPRA)
Henning Jahns
Tel.: +49-511-132214-14
Fax: +49-511-132214-99
delticom@insignis.de
or
Delticom AG
Anne Lena Peters
Tel.: +49-511-93634-8909
Fax: +49-511-93634-8301
anne.lena.peters@delti.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Boehringer Ingelheim Marks Great Progress in Immuno-oncology Research Partnerships in 201711.12.2017 13:00Pressemelding

2017 marks a year of significant advancement for Boehringer Ingelheim as it secured a range of external partnerships with the goal of transforming the lives of patients and winning the fight against cancer. External partnerships complement Boehringer Ingelheim’s two-pronged research strategy – investigating both cancer cell-directed therapies and immune cell-directed therapies. This multi-faceted approach offers the potential to bring innovative opportunities to the Boehringer Ingelheim oncology portfolio and novel therapies to patients. “Immuno-oncology is radically shifting the research and treatment landscape in oncology. We believe that the greatest success in difficult-to-treat cancers will be achieved with immuno-oncology and its combination with cancer cell directed therapy, which is why we are committing significant resources in both areas,” said Jonathon Sedgwick, Ph.D., Vice

Valence Advises SK Capital on Its Acquisition of ICL’s Fire Safety and Oil Additives Businesses11.12.2017 12:47Pressemelding

The Valence Group acted as lead financial advisor to SK Capital Partners on its announced acquisition of the Fire Safety and Oil Additives businesses of Israel Chemicals Ltd. (“ICL”) for approximately $1 billion. The transaction is expected to close during the first half of 2018. The Businesses, headquartered in St. Louis, Missouri, have global operations and are market leaders in each of their segments. The ICL Fire Safety business is a formulator and manufacturer of fire management chemicals. Its Phos-Chek fire retardants, Class A and B foams, and water enhancing gels are the world’s leading chemical solutions for managing wildland, military, industrial and municipal fires, and are used in partnership with fire management agencies across the globe. The ICL Oil Additives business provides high quality phosphorus pentasulfide used in the preparation of ZDDP-based lubricant additives, i

Smith & Nephew Announce European Launch of Handheld Imaging Technology Heralding a New Era of Evidence-Based Decision Making in Wound Care11.12.2017 10:18Pressemelding

Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announces the European launch of MolecuLight i:X TM, the easy to use, handheld imaging device that instantly measures wound surface area and visualises the presence and distribution of potentially harmful bacteria in wounds.2,3 This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171211005434/en/ Currently wound assessments are made with the naked eye which can lack the accuracy required to most effectively guide clinical decision making.4 Using fluorescence, MolecuLight i:X quickly, safely, and easily visualises potentially harmful bacteria1,2,3 in wounds which may otherwise lack signs or symptoms of infection. It enhances a clinician’s ability to choose the right therapy, at the right time for their patient1,

Dr Amal Al Qubaisi Wins Parliamentarian Excellence Award as Best President of Arab Parliament11.12.2017 09:41Pressemelding

The Arab Inter-Parliamentary Union (AIPU) has honored Her Excellency Dr Amal Al Qubaisi, Speaker of the Federal National Council (FNC) – the United Arab Emirates parliament, with the Parliamentarian Excellence Award in the Presidents of Arab Parliaments category. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171211005411/en/ Her Excellency Dr Amal Al Qubaisi, Speaker of the Federal National Council (FNC) – the UAE parliament (Photo: AETOSWire) The award honors Al Qubaisi as ‘first female leader of a parliament in the Arab world’, celebrating her achievements on a national, regional and global scale, as well as the accomplishments made by FNC under her leadership. It also acknowledges the pioneering parliamentarian initiatives, projects and programs she has spearheaded and her significant contr

Financial Market Regulator Grants EU Payment License to DIMOCO Payment Services11.12.2017 08:00Pressemelding

The Austrian Financial Market Authority (FMA) granted a license under the Payment Service Act to DIMOCO Payment Services . The awarded license allows DIMOCO Payment Services to contribute to the payment value chain, offering merchants a single technical interface and a unified clearing & settlement process for many payment methods, including credit cards, online bank transfers, SEPA and direct debit cards. “We differ from most PSPs in the global payments ecosystem with our personal touch,” said Boris Kersten, Managing Director of DIMOCO Payment Services. “We proactively and personally monitor the overall payment process. In addition to monitoring individual transactions, we make recommendations and take actions to decrease chargebacks and fraudulent transactions. This process is not simply left to algorithms, the human element is added to the mix resulting in the protec

Top UK university hospital unveils data that support the use of rapid infusion for Truxima® (CT-P10, biosimilar rituximab) in patients with advanced-stage follicular lymphoma11.12.2017 08:00Pressemelding

New data from University College London Hospitals NHS Foundation Trust (UCLH) on the safety and tolerability of rapid infusion of CT-P10 were presented this weekend at the 59th American Society of Hematology (ASH) Annual Meeting. The results showed that rapid infusion of CT-P10 was well-tolerated across all patient groups and patients could be safely switched from reference rituximab to CT-P10 without reverting to slower infusion rates1. The independent study examined the infusion-related reactions (IRRs) in three different patient groups: rituximab naive, those switching directly from reference rituximab to CT-P10, and those that received their last dose of reference rituximab at least 6 months prior to the study.1 The administration of rituximab is associated with IRRs which occur most frequently during the first infusion. To reduce the risk of IRRs, it is the man

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom